Royalty Pharma: all contributions
2025–2026 · Reported individual contributions grouped by employer.
These are contributions by individuals, not by their employer, industry, or location. Refunds remain negative; memo-only rows are marked and are not additional money.
← Back to Royalty Pharma| # | Reported contributor / location | Reported employer / occupation | Recipient / reporting committee | Date ↕ | Amount ↓ | Election | Filing details / source |
|---|---|---|---|---|---|---|---|
| 1 | URIST, MARSHALLMANHATTANNY10007 | BIOTECHNOLOGYROYALTY PHARMA | ACTBLUEC00401224 | 2025-11-16 | $5,000 | Not reported | EARMARKED FOR DAN GOLDMAN FOR NY (C00816660)Filing 1953256 · amendedFEC filing ↗ |
| 2 | URIST, MARSHALLNEW YORKNY10007 | DIRECTOR RESEARCH AND INVESTMENTSROYALTY PHARMA | DAN GOLDMAN FOR NEW YORKC00816660 | 2025-11-16 | $5,000 | Primary 2026 (P2026) | * EARMARKED CONTRIBUTION: SEE BELOWFiling 1943623FEC filing ↗ |
| 3 | URIST, MARSHALLNEW YORKNY10007 | DIRECTORROYALTY PHARMA | NEW JERSEY DEMOCRATIC STATE COMMITTEEC00104471 | 2026-02-22 | $5,000 | Primary (P) | * EARMARKED CONTRIBUTION: SEE BELOW EARMARKED CONTRIBUTION THROUGH ACTBLUEFiling 1955425FEC filing ↗ |
| 4 | URIST, MARSHALLNEW YORKNY10007 | BIOTECH FINANCEROYALTY PHARMA | ACTBLUEC00401224 | 2026-02-22 | $5,000 | Primary (P) | EARMARKED FOR NEW JERSEY DEMOCRATIC STATE COMMITTEE - VICTORY FEDERAL 2020 (C00104471)Filing 1955709FEC filing ↗ |
| 5 | URIST, MARSHALLNEW YORKNY10007 | DIRECTORROYALTY PHARMA | NEW YORK MAJORITY FUNDC00831164 | 2025-04-24 | $5,000 | Primary (P) | * EARMARKED CONTRIBUTION: SEE BELOWFiling 1908968FEC filing ↗ |
| 6 | URIST, MARSHALLMANHATTANNY10007 | BIOTECHNOLOGYROYALTY PHARMA | ACTBLUEC00401224 | 2025-04-24 | $5,000 | Not reported | EARMARKED FOR NEW YORK MAJORITY FUND (C00831164)Filing 1909062FEC filing ↗ |
| 7 | URIST, MARSHALLNEW YORKNY10007 | DIRECTORROYALTY PHARMA | NEW YORK MAJORITY FUNDC00831164 | 2026-01-18 | $5,000 | Primary (P) | * EARMARKED CONTRIBUTION: SEE BELOWFiling 1964742FEC filing ↗ |
| 8 | URIST, MARSHALLNEW YORKNY10007 | BIOTECH FINANCEROYALTY PHARMA | ACTBLUEC00401224 | 2026-01-18 | $5,000 | Primary (P) | EARMARKED FOR NEW YORK MAJORITY FUND (C00831164)Filing 1949164FEC filing ↗ |
| 9 | URIST, MARSHALLNEW YORKNY10007 | INVESTORROYALTY PHARMA | MCMORROW FOR MICHIGANC00901173 | 2025-12-09 | $2,500 | Primary 2026 (P2026) | Filing 1943320FEC filing ↗ |
| 10 | TILAK, GAURIEMANHATTANNY10023 | BUSINESSROYALTY PHARMA | ACTBLUEC00401224 | 2025-12-19 | $2,000 | Not reported | EARMARKED FOR LASHER FOR CONGRESS (C00918565)Filing 1953256 · amendedFEC filing ↗ |
| 11 | TILAK, GAURIENEW YORKNY10023 | BUSINESSROYALTY PHARMA | LASHER FOR CONGRESSC00918565 | 2025-12-19 | $2,000 | Primary 2026 (P2026) | * EARMARKED CONTRIBUTION: SEE BELOWFiling 1992985 · amendedFEC filing ↗ |
| 12 | URIST, MARSHALLNEW YORKNY10007 | DIRECTOR RESEARCH AND INVESTMENTSROYALTY PHARMA | DAN GOLDMAN FOR NEW YORKC00816660 | 2025-11-17 | $1,500Memo only · not additional money | General 2026 (G2026) | * REDESIGNATED FROM PRIMARY 2026Filing 1943623FEC filing ↗ |
| 13 | URIST, MARSHALLNEW YORKNY10007 | BIOTECHNOLOGYROYALTY PHARMA | GALLANT FOR CONGRESSC00914770 | 2025-08-05 | $1,450 | Primary 2026 (P2026) | * EARMARKED CONTRIBUTION: SEE BELOWFiling 1920295FEC filing ↗ |
| 14 | URIST, MARSHALLMANHATTANNY10007 | BIOTECHNOLOGYROYALTY PHARMA | ACTBLUEC00401224 | 2025-08-05 | $1,450 | Not reported | EARMARKED FOR GALLANT FOR CONGRESS (C00914770)Filing 1953256 · amendedFEC filing ↗ |
| 15 | URIST, MARSHALLNEW YORKNY10007 | BIOTECHNOLOGYROYALTY PHARMA | MCMORROW FOR MICHIGANC00901173 | 2026-01-30 | $1,000 | Primary 2026 (P2026) | Filing 1966642FEC filing ↗ |
| 16 | URIST, MARSHALLMANHATTANNY10007 | BIOTECHNOLOGYROYALTY PHARMA | ACTBLUEC00401224 | 2025-11-16 | $500 | Not reported | CONTRIBUTION TO ACTBLUEFiling 1953256 · amendedFEC filing ↗ |
| 17 | URIST, MARSHALLMANHATTANNY10007 | BIOTECHNOLOGYROYALTY PHARMA | ACTBLUEC00401224 | 2025-08-05 | $145 | Not reported | CONTRIBUTION TO ACTBLUEFiling 1953256 · amendedFEC filing ↗ |
| 18 | URIST, MARSHALLNEW YORKNY10007 | DIRECTOR RESEARCH AND INVESTMENTSROYALTY PHARMA | DAN GOLDMAN FOR NEW YORKC00816660 | 2025-11-17 | -$1,500Memo only · not additional money | Primary 2026 (P2026) | * REDESIGNATED TO GENERAL 2026Filing 1943623FEC filing ↗ |
One page is fetched at a time, with one extra row to check for the next page. Current amendment versions are selected before pagination. Raw reported names and filing values are preserved. This list covers locally ingested FEC individual-contribution records, not undisclosed or unitemized contributor identities.